Joe Ensor

9.1k total citations · 1 hit paper
166 papers, 6.3k citations indexed

About

Joe Ensor is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joe Ensor has authored 166 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 47 papers in Surgery and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joe Ensor's work include Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer Treatment and Pharmacology (12 papers). Joe Ensor is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer Treatment and Pharmacology (12 papers). Joe Ensor collaborates with scholars based in United States, China and United Kingdom. Joe Ensor's co-authors include Sanjay Gupta, Gabriel N. Hortobágyi, Donald A. Berry, Constance Johnson, Caimiao Wei, Christopher I. Amos, Derek J. Smolenski, Bernard Levin, Michael B. Wallace and Kartik Anand and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joe Ensor

162 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Meta-analyses of colorectal cancer risk factors

2013 571 citations Constance Johnson, Joe Ensor et al. profile →

Peers

Countries citing papers authored by Joe Ensor

Since Specialization

Citations

This map shows the geographic impact of Joe Ensor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joe Ensor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joe Ensor more than expected).

Fields of papers citing papers by Joe Ensor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joe Ensor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joe Ensor. The network helps show where Joe Ensor may publish in the future.

Co-authorship network of co-authors of Joe Ensor

This figure shows the co-authorship network connecting the top 25 collaborators of Joe Ensor. A scholar is included among the top collaborators of Joe Ensor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joe Ensor. Joe Ensor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), Névine Zariffa, Katherine K. Nishimura, Yu Deng, (unknown), Joe Ensor, Carin R. Espenschied, David Fabrizio, Emily Goren, Vincent Haddad, Minetta C. Liu, Dimple Modi, Achim K. Moesta, Katie Quinn, (unknown), Diana Merino Vega, (unknown), Antje Hoering, Mark Stewart, Jeff Allen	0
2	BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours 2022 ·BMJ Open ·Pashtoon Murtaza Kasi, Sakti Chakrabarti, Sarah Sawyer, (unknown), Andrew Poklepovic, George Ansstas, (unknown), Meenakshi Malhotra, Joe Ensor, Ling Gao, Zeynep Eroglu, (unknown), Paul R. Billings, Angel Rodriguez, Alexey Aleshin	9
3	G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg? 2021 ·Annals of Hematology ·J.G. Youssef, (unknown), George J. Youssef, Sriram Padmanabhan, Joe Ensor, Sai Ravi Pingali, Youli Zu, Sandeep Sahay, Swaminathan P. Iyer	20
4	T-cell lymphoma secondary to checkpoint inhibitor therapy 2020 ·Journal for ImmunoTherapy of Cancer ·Kartik Anand, Joe Ensor, Sai Ravi Pingali, Patrick Hwu, Madeleine Duvic, Stephen Chiang, Roberto N. Miranda, Youli Zu, Swaminathan P. Iyer	33
5	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer 2020 ·The Oncologist ·Bora Lim, Juhee Song, Nuhad K. Ibrahim, Kimberly B. Koenig, Mariana Chávez‐MacGregor, Joe Ensor, (unknown), Savitri Krishnamurthy, Abigail S. Caudle, Simona F. Shaitelman, Gary J. Whitman, Vicente Valero	5
6	Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic 2020 ·JCO Oncology Practice ·Jorge Darcourt, (unknown), (unknown), Joe Ensor, Eva Zsigmond, Stephen T.C. Wong, (unknown), Mamta Puppala, (unknown), Charles E. Geyer, Robert A. Phillips, Roberta Schwartz, Jenny C. Chang	80
7	Primary and Secondary Central Nervous System Lymphoma: Outcomes from Houston Methodist Cancer Center 2020 ·Blood ·(unknown), Ethan Burns, Ibrahim N. Muhsen, (unknown), (unknown), John Rogers, Matthew D. Cykowski, Joe Ensor, Kirk Heyne, Jorge Darcourt, Jasleen K. Randhawa, (unknown), Sai Ravi Pingali	0
8	A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study) 2019 ·Breast Cancer Research ·Tejal Patel, Joe Ensor, (unknown), (unknown), Angel Rodriguez, (unknown), Jorge Darcourt, Jane Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Roberto R. Rosato, Wei Qian, Anna Belcheva, Mary R. Schwartz, Virginia Kaklamani, Jenny C. Chang	48
9	Osimertinib-Induced Cardiotoxicity 2019 ·JACC CardioOncology ·Kartik Anand, Joe Ensor, Barry Trachtenberg, Eric Bernicker	141
10	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway 2018 ·Clinical Cancer Research ·Liana Adam, F. Anthony San Lucas, Richard Fowler, Yao Yu, Wenhui Wu, Yulun Liu, Huamin Wang, David G. Menter, Michael T. Tetzlaff, Joe Ensor, Ganiraju C. Manyam, Stefan T. Arold, Chad Huff, Scott Kopetz, Paul Scheet, Michael J. Overman	19
11	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center 2018 ·PLoS ONE ·Tamer M. Fouad, Naoto T. Ueno, Robert Yu, Joe Ensor, Ricardo H. Álvarez, Savitri Krishnamurthy, Anthony Lucci, James M. Reuben, Wei Yang, Jie Willey, Vicente Valero, Melissa L. Bondy, (unknown), Sanjay Shete, Wendy A. Woodward, Randa El‐Zein	23
12	Underreporting of Research Biopsies from Clinical Trials in Oncology 2017 ·Clinical Cancer Research ·Christine M. Parseghian, Kanwal Raghav, Robert A. Wolff, Joe Ensor, James C. Yao, Lee M. Ellis, Alda L. Tam, Michael J. Overman	14
13	An Integer Weighted Genomic Mutation Score (GMS) Using Next Generation Sequencing Is Predictive of Prognosis in Intermediate Risk AML Patients 2017 ·Blood ·(unknown), Xinyu Nan, Joe Ensor, Jasleen K. Randhawa, Sai Ravi Pingali, Arthur W. Zieske, Randall J. Olsen, (unknown), Swaminathan P. Iyer	1
14	Heparin-Induced Thrombocytopenia with Very High Antibody Titer Is Associated with Slower Platelet Recovery 2017 ·Blood ·(unknown), Asmita Patel, Joe Ensor, (unknown), Kelty R. Baker, Lawrence Rice	1
15	An injectable nanoparticle generator enhances delivery of cancer therapeutics 2016 ·Nature Biotechnology ·Rong Xu, Guodong Zhang, Junhua Mai, Xiaoyong Deng, Víctor Segura-Ibarra, Suhong Wu, Jianliang Shen, Haoran Liu, Zhenhua Hu, Lingxiao Chen, Yi Huang, Eugene J. Koay, Yu Huang, Jun Liu, Joe Ensor, Elvin Blanco, Xuewu Liu, Mauro Ferrari, Haifa Shen	228
16	Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients 2015 ·Breast Cancer Research and Treatment ·Diana H. Liang, Joe Ensor, (unknown), Asmita Patel, Tejal Patel, Jenny C. Chang, Angel Rodriguez	46
17	CT‐guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions 2009 ·Hematological Oncology ·Sanjay Gupta, (unknown), Jorge Romaguera, Joe Ensor, Savitri Krishnamurthy, Michael B. Wallace, Kamran Ahrar, David C. Madoff, Ravi Murthy, Marshall E. Hicks	38
18	14-3-3ζ Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival 2009 ·Cancer Research ·Christopher L. Neal, Jun Yao, Wentao Yang, Xiaoyan Zhou, (unknown), Jing Lü, Christopher G. Danes, Hua Guo, Keng‐Hsueh Lan, Joe Ensor, Walter N. Hittelman, Mien‐Chie Hung, Dihua Yu	158
19	Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors 2006 ·Cancer ·Katsuhiro Kobayashi, Sanjay Gupta, Jonathan C. Trent, Jean‐Nicolas Vauthey, Savitri Krishnamurthy, Joe Ensor, Kamran Ahrar, Michael B. Wallace, David C. Madoff, Ravi Murthy, Stephen E. McRae, Marshall E. Hicks	50
20	An Informatics Tool to Assess Individualized Colon Cancer Risk 2005 ·Europe PMC (PubMed Central) ·Constance Johnson, Joe Ensor, Christopher I. Amos, Margaret R. Spitz, Susan K. Peterson, Bernard Levin, Donald A. Berry	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact